https://www.ejpn-journal.com/article/S1090-3798(22)00059-9/fulltext

Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, Flet-Berliac L, de Chalus A, Adamsbaum C, Capobianco M, Laetitia G, Hacohen Y, Hemingway C, Wassmer E, Lim M, Baumann M, Wickström R, Armangue T, Rostasy K, Deiva K, Neuteboom RF. E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:41-53. doi: 10.1016/j.ejpn.2020.10.005. Epub 2020 Nov 4. PMID: 33176999.

Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, Wassmer E; E.U. paediatric MOG consortium, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi: 10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4. PMID: 33162302.

Waubant E, Banwell B, Wassmer E, Sormani MP, Amato MP, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T; IPMSSG. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology. 2019 May 28;92(22):e2538-e2549. doi: 10.1212/WNL.0000000000007572. Epub 2019 May 1. Erratum in: Neurology. 2019 Oct 1;93(14):647. PMID: 31043474; PMCID: PMC6556085.

Tardieu M, Banwell B, Wolinsky JS, Pohl D, Krupp LB. Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology. 2016 Aug 30;87(9 Suppl 2):S8-S11. doi: 10.1212/WNL.0000000000002877. PMID: 27572866